

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/518,818	First Named Inventor: Bailey et al.
371 Filing Date: Dec. 20, 2004	Attorney Docket No.: 100730-1P US
Examiner: GRAFFEO, Michel	Group Art Unit: 1614
Customer No.: 22466	Confirmation No.: 8247
Title: Novel Compounds	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO THE RESTRICTION REQUIREMENT

Sir:

The present Response is filed in regard to the Restriction Requirement dated July 27, 2006 in connection with the above-identified patent application.

In the Restriction Requirement, the Examiner restricted pending claims into four groups:

Group I, claim(s) 1-7, drawn to a method of inhibiting Cathepsin S.

Group II, claim(s) 9, drawn to a pharmaceutical composition.

Group III, claim(s) 10-11, drawn to a method for producing inhibition of a cysteine.

Group IV, claim(s) 12, drawn to a method for treating pain.

Applicants elect Group I, claims 1-7, with traverse.

The Examiner has further averred that claim 1 encompassed multiple and patentably distinct species, which are enumerated as follows.

Specie 1: the compound of formula (I) when A comprises an O

Specie 2: the compound of formula (I) when A comprises an O

Specie 3: the compound of formula (I) when A comprises no heteroatom.

The Examiner requests that Applicants elect a single specie. Applicants elect Specie 3, when A comprises no heteroatom, with traverse. Applicants submit that this election is sufficient for searching purposes. Should the Examiner require additional moieties to be elected,

Applicants further elect the following additional moieties: R¹ and R² together with the nitrogen atom to which they are attached form an unsubstituted morpholine ring or a piperidine ring substituted by a group -(CH₂)_p-R⁶ where p is 0 to 3 and R⁶ is C₁₋₆ alkyl; R³ is hydrogen; R⁴ is hydrogen, R⁵ is hydrogen or phenyl optionally substituted by C₁₋₆ alkyl or C₁₋₆ alkoxy. Claims 1-7 are readable on the election made. Support for the election made can be found, for example, in the original claims 1-6.

A petition for a one month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100730-1P US.

Although Applicants believe no excess claim fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100730-1P US.

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076/

Name: Jianzhong Shen
Dated: 8/31/2006
Reg. No.: 48076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437